Skip to main content

Table 2 Initial biochemical parameters of the patients in the intention-to-treat population

From: Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study

  Placebo (n = 87) Pentoxifylline (n = 87) P-value
Serum Cr (mg/dL) 0.9 ± 0.3 0.9 ± 0.2 0.165
Urinary Cr (mg/dL) 103 (72-136) 86 (61-122) 0.176
eGFR (ml/min per 1.73 m2) 85.4 ± 27.0 88.8 ± 24.8 0.401
Proteinuria (mg/g) 395 (229–714) 371 (218–610) 0.689
Albuminuria (mg/g) 203 (88-513) 143 (71-315) 0.201
Fasting plasma glucose (mg/dL) 140 ± 35 138 ± 35 0.795
HbA1c (%) 7.2 ± 0.8 7.5 ± 0.9 0.043
AST(U/L) 26.5 ± 14.9 24.8 ± 8.7 0.368
ALT(U/L) 26.5 ± 18.0 26.3 ± 12.4 0.910
r-GT(U/L) 39.0 ± 36.2 35.4 ± 32.9 0.515
hs-CRP (mg/L) 1.7 ± 2.3 1.8 ± 2.8 0.667
Serum TNF-α (pg/mL) 1.4 ± 1.4 1.6 ± 2.8 0.570
  1. Data are presented as means ± standard deviation (SD) or medians (interquartile ranges)
  2. Cr creatinine, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, AST aspartate aminotransferase, ALT alanine aminotransferase, r-GT r-glutamyl transpeptidase, hs-CRP high-sensitivity C-reactive protein, TNF tumor necrosis factor
  3. The independent t-test or Mann–Whitney U-test was used to compare continuous variables between the groups according to the normality assumption